Proniosomal Gel Loaded With Antiglaucoma Drug For Prolonged Ocular Drug Delivery

Abstract

newline This study aimed to formulate and evaluate Acetazolamide loaded proniosomal gels for treating glaucoma.Results of preformulation studies were found well within the limit.Neumarical optimidation formulation is done,is prepared by coacervation phase separation method by factorial design..Evaluation is done based on vesicle size, and the range was found ideal for ocular drug delivery.Its zeta potential value suggests the formation of uniform nanovesicles with high physical stability. The %EE, of the optimized formulations was determined to be 79.24 ± 2.82%.The pH of the same was found to be 6.9±0.15, indicate that the gels have a slightly acidic to neutral pH. The ACZ niosomal gel exhibits a non-Newtonian shear thinning behavior with an average viscosity of 10805±0.72 cps. Invitro drug release study of the prepared formulation was performed. The release characteristics of the optimized formulation was biphasic, morphological characteristics of the niosomes derived from the prepared proniosomal gel revealed well-formed spherical structures. The size of the niosomes observed under TEM the zeta sizer was found comparable. Niosomal gel formulation exhibited good physical form and homogeneity during stability study. Ex vivo corneal permeation of ACZ from the plain ACZ suspension was faster than optimized proniosomal gel formulation. However, the prepared formulation exhibited sustained permeation of ACZ, lasting for duration of 6 hours. The formulation showed favorable permeability characteristics with a permeability coefficient of 0.000264cm²/h and a steady-state flux of 2.64 µg/cm²/h. These values indicate the efficiency of the formulation in facilitating the passage of ACZ through the corneal membrane.For the invivo study, Draize test showed absence of any signs of inflammation.Its Cmax after 4 hours, was 21 times more than the Cmax of the ACZ drug suspension obtained after 2 hours. Hence,the study concluded that the ACZ-loaded proniosomal gels with improved ocular bioavailability and sustained drug